{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:19:10Z","timestamp":1790180350851,"version":"4.1.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Pulmonary hypertension due to left heart disease (PH-LHD) represents approximately 65%\u201380% of all patients with PH. The progression, prognosis, and mortality of individuals with left heart failure (LHF) are significantly influenced by PH and right ventricular (RV) dysfunction. Consequently, cardiologists should devote ample attention to the interplay between HF and PH. Patients with PH and HF may not receive optimal benefits from the therapeutic effects of prostaglandins, endothelin receptor antagonists, or phosphodiesterase inhibitors, which are specific drugs for pulmonary arterial hypertension (PAH). Sacubitril\/valsartan, the angiotensin receptor II blocker-neprilysin inhibitor (ARNI), was recommended as the first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF) by the 2021 European Society of Cardiology Guidelines. Although ARNI is effective in treating left ventricular (LV) enlargement and lower ejection fraction, its efficacy in treating individuals with PH and HF remains underexplored. Considering its vasodilatory effect at the pre-capillary level and a natriuretic drainage role at the post-capillary level, ARNI is believed to have a broad range of potential applications in treating PH-LHD. This review discusses the fundamental pathophysiological connections between PH and HF, emphasizing the latest research and potential benefits of ARNI in PH with various types of LHF and RV dysfunction.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1125014","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:37:50Z","timestamp":1684395470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The emerging role of sacubitril\/valsartan in pulmonary hypertension with heart failure"],"prefix":"10.3389","volume":"10","author":[{"given":"Yu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjiao","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglu","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"694240","DOI":"10.3389\/fcvm.2021.694240","article-title":"Pulmonary hypertension in patients with heart failure with mid-range ejection fraction","volume":"8","author":"Maeder","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/ehf2.13386","article-title":"Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction","volume":"8","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jcmg.2016.12.024","article-title":"RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes","volume":"10","author":"Guazzi","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.114.006980","article-title":"Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension","volume":"131","author":"Maron","year":"2015","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1086\/675984","article-title":"The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 grover conference series)","volume":"4","author":"Maron","year":"2014","journal-title":"Pulm Circ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.ejim.2017.07.016","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: drug safety and tolerability","volume":"44","author":"Correale","year":"2017","journal-title":"Eur J Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2018.05.124","article-title":"Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction","volume":"281","author":"Docherty","year":"2019","journal-title":"Int J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1378\/chest.110.5.1220","article-title":"Atrial natriuretic peptide and brain natriuretic peptide in corpulmonale. Hemodynamic and endocrine effects","volume":"110","author":"Cargill","year":"1996","journal-title":"Chest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1164\/rccm.200404-455OC","article-title":"C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"170","author":"Itoh","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0306-3623(96)00275-3","article-title":"Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds","volume":"28","author":"Arjona","year":"1997","journal-title":"Gen Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/ppul.22904","article-title":"B-type natriuretic peptide inhibits angiotensin II-induced proliferation and migration of pulmonary arterial smooth muscle cells","volume":"49","author":"Hsu","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2217\/fca-2020-0002","article-title":"Current evidence of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction","volume":"16","author":"Abumayyaleh","year":"2020","journal-title":"Future Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijcard.2018.06.060","article-title":"Sacubitril\/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives","volume":"281","author":"Gori","year":"2019","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","article-title":"Pulmonary arterial hypertension","volume":"114","author":"McLaughlin","year":"2006","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40256-022-00525-w","article-title":"Hemodynamic effects of sacubitril\/valsartan in patients with reduced left ventricular ejection fraction over 24 months: a retrospective study","volume":"22","author":"Abumayyaleh","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e006696","DOI":"10.1161\/CIRCHEARTFAILURE.119.006696","article-title":"Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation","volume":"13","author":"Zern","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.21037\/atm-20-4038","article-title":"Narrative review in the current role of angiotensin receptor-neprilysin inhibitors","volume":"9","author":"Cruz Rodriguez","year":"2021","journal-title":"Ann Transl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J Hypertens"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1755-5922.12053","article-title":"Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat","volume":"32","author":"Dalzell","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40292-015-0112-5","article-title":"Angiotensin II receptor blocker neprilysin inhibitor (ARNI): new avenues in cardiovascular therapy","volume":"22","author":"Volpe","year":"2015","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40292-017-0194-3","article-title":"Current pharmacological therapies in heart failure patients","volume":"24","author":"Muiesan","year":"2017","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/fca-2019-0089","article-title":"ARNI In cardiovascular disease: current evidence and future perspectives","volume":"16","author":"Kuchulakanti","year":"2020","journal-title":"Future Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.2217\/pgs.14.76","article-title":"Functional role of miRNA in cardiac resynchronization therapy","volume":"15","author":"Sardu","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e015640","DOI":"10.1161\/JAHA.119.015640","article-title":"Sacubitril\/valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal miR-181a in a rodent chronic myocardial infarction model","volume":"9","author":"Vaskova","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"106303","DOI":"10.1016\/j.phrs.2022.106303","article-title":"Angiotensin receptor\/neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside","volume":"182","author":"Sardu","year":"2022","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/bph.14968","article-title":"Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension","volume":"177","author":"Maron","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1165\/rcmb.2012-0506OC","article-title":"Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension","volume":"50","author":"Batt","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1164\/rccm.201209-1663PP","article-title":"Neurohormonal axis in patients with pulmonary arterial hypertension: friend or foe?","volume":"187","author":"de Man","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jacc.2021.01.052","article-title":"Myocardial angiotensin metabolism in End-stage heart failure","volume":"77","author":"Pavo","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-022-01573-x","article-title":"Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts","volume":"21","author":"Marfella","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1113\/expphysiol.2008.042002","article-title":"Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis","volume":"93","author":"Santos","year":"2008","journal-title":"Exp Physiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bcp.2007.08.012","article-title":"Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system","volume":"75","author":"Lambert","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","article-title":"Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion","volume":"35","author":"Sun","year":"1997","journal-title":"Cardiovasc Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension","volume":"186","author":"deMan","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"H2319","DOI":"10.1152\/ajpheart.00518.2005","article-title":"Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension","volume":"289","author":"Rondelet","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.healun.2009.01.016","article-title":"Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension","volume":"28","author":"Chung","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.clinbiochem.2004.06.002","article-title":"The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension","volume":"37","author":"Yap","year":"2004","journal-title":"Clin Biochem"},{"key":"B43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ejheart.2007.01.010","article-title":"Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease","volume":"9","author":"Rutten","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"B44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1378\/chest.129.2.417","article-title":"Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension","volume":"129","author":"Klinger","year":"2006","journal-title":"Chest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1210\/jcem.76.2.8432776","article-title":"The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects","volume":"76","author":"Wijeyaratne","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cardfail.2005.01.009","article-title":"Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension","volume":"11","author":"Michaels","year":"2005","journal-title":"J Card Fail"},{"key":"B47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cardfail.2006.05.004","article-title":"Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension","volume":"12","author":"Khush","year":"2006","journal-title":"J Card Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jama.287.12.1531","article-title":"Publication committee for the VMAC investigators (vasodilatation in the management of acute CHF). intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"Br Med J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1378\/chest.13-1510","article-title":"Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure","volume":"145","author":"Pellegrini","year":"2014","journal-title":"Chest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1183\/09031936.00074312","article-title":"The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease","volume":"41","author":"Naeije","year":"2013","journal-title":"Eur Respir J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1378\/chest.12-1653","article-title":"Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in \u201cout-of-proportion\u201d pulmonary hypertension","volume":"143","author":"Gerges","year":"2013","journal-title":"Chest"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/HYPERTENSIONAHA.119.14330","article-title":"Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy","volume":"75","author":"Al-Omary","year":"2020","journal-title":"Hypertension"},{"key":"B56","doi-asserted-by":"publisher","first-page":"781011","DOI":"10.3389\/fgene.2021.78101","article-title":"Construction of a support vector machine-based classifier for pulmonary arterial hypertension patients","volume":"12","author":"Shang","year":"2021","journal-title":"Front Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.healun.2006.06.015","article-title":"Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure","volume":"25","author":"Grigioni","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1164\/rccm.201503-0529OC","article-title":"Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival","volume":"192","author":"Gerges","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2017.06.006","article-title":"Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: similarities and disparities","volume":"192","author":"Adir","year":"2017","journal-title":"Am Heart J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jccase.2019.08.006","article-title":"Reduction in pulmonary artery pressures with use of sacubitril\/valsartan","volume":"20","author":"De Simone","year":"2019","journal-title":"J Cardiol Cases"},{"key":"B62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/eurjhf\/hfq014","article-title":"Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study","volume":"12","author":"Bursi","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"B64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jacc.2011.08.067","article-title":"Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (endovascular valve edge-to-edge repair) high risk study","volume":"59","author":"Whitlow","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e010114","DOI":"10.1161\/JAHA.118.010114","article-title":"Diastolic ventricular interaction in heart failure with preserved ejection fraction","volume":"8","author":"Parasuraman","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/ehf2.13285","article-title":"Reverse remodelling by sacubitril\/valsartan predicts the prognosis in heart failure with reduced ejection fraction","volume":"8","author":"Moon","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1038\/s41598-020-63801-2","article-title":"Clinical and echocardiographic benefit of sacubitril\/valsartan in a real-world population with HF with reduced ejection fraction","volume":"10","author":"Polito","year":"2020","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","first-page":"100656","DOI":"10.1016\/j.ijcha.2020.100656","article-title":"Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction","volume":"31","author":"Landolfo","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ehf2.13225","article-title":"Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction","volume":"8","author":"Tran","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.rmed.2015.06.005","article-title":"The role of pulmonary arterial stiffness in COPD","volume":"109","author":"Weir-McCall","year":"2015","journal-title":"Respir Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1253\/circj.CJ-10-1310","article-title":"Cardiac magnetic resonance imaging-derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension","volume":"75","author":"Kang","year":"2011","journal-title":"Circ J"},{"key":"B72","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10554-020-01973-8","article-title":"Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction","volume":"37","author":"Yener\u00e7a\u011f","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in world health organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J Card Fail"},{"key":"B75","doi-asserted-by":"publisher","first-page":"734697","DOI":"10.3389\/fcvm.2021.734697","article-title":"Reduction of pulmonary hypertension after transition to sacubitril\/valsartan in patients with heart failure with preserved ejection fraction","volume":"8","author":"Burgdorf","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10741-022-10282-2","article-title":"Heart failure study group of the Italian society of cardiology. Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis","author":"Dini","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1086\/682223","article-title":"The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 grover conference series)","volume":"5","author":"Bristow","year":"2015","journal-title":"Pulm Circ"},{"key":"B79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ehf2.13665","article-title":"Less loop diuretic use in patients on sacubitril\/valsartan undergoing remote pulmonary artery pressure monitoring","volume":"9","author":"B\u00f6hm","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2045894019868620","DOI":"10.1177\/2045894019868620","article-title":"EXPRESS: cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure","volume":"9","author":"Mercurio","year":"2019","journal-title":"Pulm Circ"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1165\/rcmb.2013-0149OC","article-title":"Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-\u03b21 signaling and is abrogated by angiotensin receptor blockade","volume":"49","author":"Friedberg","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1254\/jphs.09112fp","article-title":"Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats","volume":"111","author":"Okada","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2013.08.102","article-title":"A cornerstone of heart failure treatment is not effective in experimental right ventricular failure","volume":"169","author":"Borgdorff","year":"2013","journal-title":"Int J Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5152\/akd.2010.010","article-title":"Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension","volume":"10","author":"Bozba\u015f","year":"2010","journal-title":"Anadolu Kardiyol Derg"},{"key":"B85","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/cpf.12726","article-title":"Predictors of right ventricular function improvement with sacubitril\/valsartan in a real-life population of patients with chronic heart failure","volume":"41","author":"Correale","year":"2021","journal-title":"Clin Physiol Funct Imaging"},{"key":"B86","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2019.06.065","article-title":"Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure","volume":"293","author":"Andersen","year":"2019","journal-title":"Int J Cardiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e015708","DOI":"10.1161\/JAHA.119.015708","article-title":"Angiotensin receptor-neprilysin inhibition attenuates right ventricular remodeling in pulmonary hypertension","volume":"9","author":"Sharifi Kia","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e005819","DOI":"10.1161\/CIRCHEARTFAILURE.119.005819","article-title":"Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril\/valsartan","volume":"12","author":"Clements","year":"2019","journal-title":"Circ Heart Fail"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/cvr\/cvaa200","article-title":"Additive protective effects of sacubitril\/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension","volume":"117","author":"Chaumais","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11010-006-9234-3","article-title":"Identification, regulation and anti-proliferative role of the NPR-C receptor in gastric epithelial cells","volume":"293","author":"Gower","year":"2006","journal-title":"Mol Cell Biochem"},{"key":"B91","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/s0735-1097(17)35291-9","article-title":"New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease","volume":"9","author":"Egom","year":"2017","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"118877","DOI":"10.1016\/j.lfs.2020.118877","article-title":"Sacubitril\/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism","volume":"266","author":"Liu","year":"2021","journal-title":"Life Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/2150135119825599","article-title":"Early experience with sacubitril\/valsartan in adult patients with congenital heart disease","volume":"10","author":"Lluri","year":"2019","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"B94","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4103\/ijp.IJP_562_18","article-title":"Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?","volume":"51","author":"Gulin","year":"2019","journal-title":"Indian J Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/ehf2.1254495","article-title":"Sacubitril\/valsartan in heart failure and end-stage renal insufficiency","volume":"6","author":"Heyse","year":"2019","journal-title":"ESC Heart Fail"},{"key":"B96","doi-asserted-by":"publisher","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e026407","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease","volume":"11","author":"Niu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1002\/ehf2.14097","article-title":"Sacubitril\/valsartan in heart failure: efficacy and safety in and outside clinical trials","volume":"9","author":"Abdin","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/ndt\/gfw321","article-title":"Randomized multicentre pilot study of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom heart and renal protection (HARP)-III-rationale, trial design and baseline data","volume":"32","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B102","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jacc.2019.04.068","article-title":"From ACE inhibitors\/ARBs to ARNIs in coronary artery disease and heart failure (part 2\/5)","volume":"74","author":"Leong","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"B105","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/156720508783954703","article-title":"Neprilysin and amyloid beta peptide degradation","volume":"5","author":"Hersh","year":"2008","journal-title":"Curr Alzheimer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"10334","DOI":"10.1523\/JNEUROSCI.1634-17.2017","article-title":"Drosophila neprilysin 1 rescues memory deficits caused by amyloid-\u03b2 peptide","volume":"37","author":"Turrel","year":"2017","journal-title":"J Neurosci"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B109","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccm.2013.09.001","article-title":"Diagnosis of pulmonary arterial hypertension","volume":"34","author":"Forfia","year":"2013","journal-title":"Clin Chest Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2268\/221545","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10276-0","article-title":"Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction","author":"Ghio","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B112","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.ijcha.2020.100486","article-title":"Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the daunia heart failure registry","volume":"27","author":"Correale","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1164\/rccm.200604-547OC","article-title":"Tricuspid annular displacement predicts survival in pulmonary hypertension","volume":"174","author":"Forfia","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10554-017-1110-6","article-title":"Altered synchrony of right ventricular contraction in borderline pulmonary hypertension","volume":"33","author":"Lamia","year":"2017","journal-title":"Int J Cardiovasc Imaging"},{"key":"B115","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2016.03.074","article-title":"The use of multimodality cardiovascular imaging to assess right ventricular size and function","volume":"214","author":"Surkova","year":"2016","journal-title":"Int J Cardiol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/eurheartj\/ehl477","article-title":"Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension","volume":"28","author":"van Wolferen","year":"2007","journal-title":"Eur Heart J"},{"key":"B117","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/aor.12164","article-title":"Comparison of continuous-flow and pulsatile-flow blood pumps on reducing pulmonary artery pressure in patients with fixed pulmonary hypertension","volume":"37","author":"Ozturk","year":"2013","journal-title":"Artif Organs"},{"key":"B118","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.healun.2009.09.013","article-title":"Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension","volume":"29","author":"Nair","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"B119","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cardfail.2018.08.003","article-title":"Decoupling between diastolic pulmonary arterial pressure and pulmonary arterial wedge pressure at incremental left ventricular assist device (LVAD) speeds is associated with worse prognosis after LVAD implantation","volume":"24","author":"Imamura","year":"2018","journal-title":"J Card Fail"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.jacc.2017.08.058","article-title":"(Re)Discovering the neurohormonal and hemodynamic duality of heart failure","volume":"70","author":"Klein","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.108.783910","article-title":"Transition from Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained from Continuous Monitoring of Intracardiac Pressures","volume":"118","author":"Zile","year":"2008","journal-title":"Circulation"},{"key":"B122","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ahj.2007.01.041","article-title":"Repeated hospitalizations predict mortality in the community population with heart failure","volume":"154","author":"Setoguchi","year":"2007","journal-title":"Am Heart J"},{"key":"B123","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12872-018-0883-4","article-title":"The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports","volume":"18","author":"Tsch\u00f6pe","year":"2018","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1125014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:37:56Z","timestamp":1684395476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1125014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":123,"alternative-id":["10.3389\/fcvm.2023.1125014"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1125014","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1125014"}}